Top

Pediatric Radiology

Published in:

01-11-2011 | Original Article

Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions

Authors: Sophie Emond, Francis Brunelle

Published in: Pediatric Radiology | Issue 11/2011

Abstract

Background

There is a paucity of evidence with regard to the safety of contrast medium administration at MRI in neonates and infants.

Purpose

To assess immediate adverse reactions in children younger than 18 months of age during routine clinical utilization of gadoteric acid (Gd-DOTA) in a cohort of patients with nonselected indications.

Materials and methods

One hundred and four neonates and infants were enrolled in a postmarketing survey with Gd-DOTA (Dotarem, Guerbet, Roissy, France) from a single pediatric hospital. A standardized questionnaire was used to collect the patient information.

Results

All included children, ages 3 days to 18 months, received one injection of Gd-DOTA (volume 0.6–4 ml). No immediate adverse event was reported.

Conclusion

This postmarketing study involving neonates and infants suggests a favorable safety profile of Gd-DOTA in routine practice.

Burtea C, Laurent S, Vander Elst L et al (2008) Contrast agents: magnetic resonance. Handb Exp Pharmacol 185:135–165PubMedCrossRef

Hanquinet S, Christophe C, Greef DD et al (1996) Clinical evaluation of gadodiamide injection in paediatric MR imaging. Pediatr Radiol 26:806–810PubMedCrossRef

Sadowski EA, Bennett LK, Chan MR et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148–157PubMedCrossRef

Grobner T (2006) Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108PubMedCrossRef

Altun E, Semelka RC, Cakit C (2009) Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol 16:897–905PubMedCrossRef

Janus N, Launay-Vacher V, Karie S et al (2010) Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the finest study. Eur J Radiol 73:357–359PubMedCrossRef

Mendichovszky IA, Marks SD, Simcock CM et al (2008) Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol 38:489–496PubMedCrossRef

Morcos SK (2008) Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 66:175–179PubMedCrossRef

Herve-Somma CM, Sebag GH, Prieur AM et al (1992) Juvenile rheumatoid arthritis of the knee: MR evaluation with Gd-DOTA. Radiology 182:93–98PubMed

10.

Bonnerot V, Sebag G, de Montalembert M et al (1994) Gadolinium-DOTA enhanced MRI of painful osseous crises in children with sickle cell anemia. Pediatr Radiol 24:92–95PubMedCrossRef

11.

Ducou le Pointe H, Haddad S, Silberman B et al (1994) Legg-Perthes-Calve disease: staging by MRI using gadolinium. Pediatr Radiol 24:88–91PubMedCrossRef

12.

Hermans R (2006) Head and neck cancer: how imaging predicts treatment outcome. Cancer Imaging 6:S145–153PubMedCrossRef

13.

Hsu WC, Loevner LA, Karpati R et al (2005) Accuracy of magnetic resonance imaging in predicting absence of fixation of head and neck cancer to the prevertebral space. Head Neck 27:95–100PubMedCrossRef

14.

Bartels U, Shroff M, Sung L et al (2006) Role of spinal MRI in the follow-up of children treated for medulloblastoma. Cancer 107:1340–1347PubMedCrossRef

15.

Kobayashi S, Hayakawa K, Nakane T et al (2009) Visualization of intraneural edema using gadolinium-enhanced magnetic resonance imaging of carpal tunnel syndrome. J Orthop Sci 14:24–34PubMedCrossRef

16.

Drape JL, Thelen P, Gay-Depassier P et al (1993) Intraarticular diffusion of Gd-DOTA after intravenous injection in the knee: MR imaging evaluation. Radiology 188:227–234PubMed

17.

Willinek WA, Schild HH (2008) Clinical advantages of 3.0 T MRI over 1.5 T. Eur J Radiol 65:2–14PubMedCrossRef

18.

Riccabona M, Simbrunner J, Ring E et al (2002) Feasibility of MR urography in neonates and infants with anomalies of the upper urinary tract. Eur Radiol 12:1442–1450PubMedCrossRef

19.

Herborn CU, Honold E, Wolf M et al (2007) Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 42:58–62PubMedCrossRef

20.

Briand Y, Neiss AC, Vitry A (1992) Efficacy and safety of the macrocyclic complex Gd-DOTA in children: results of a multi-centre study. In: 29th congress of the European Society of Pediatric Radiology, Budapest: R12.

21.

Shellock FG, Parker JR, Pirovano G et al (2006) Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging 24:1378–1385PubMedCrossRef

22.

Kuo PH, Kanal E, Abu-Alfa AK et al (2007) Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242:647–649PubMedCrossRef

23.

Grobner T (2008) Prischl FC (2008) Patient characteristics and risk factors for nephrogenic systemic fibrosis for gadolinium exposure. Semin Dial 21:135–139PubMedCrossRef

24.

Idee JM, Port M, Dencausse A et al (2009) Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin N Am 47:855–869PubMedCrossRef

Title: Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions
Authors: Sophie Emond
Francis Brunelle
Publication date: 01-11-2011
Publisher: Springer-Verlag
Published in: Pediatric Radiology / Issue 11/2011
Print ISSN: 0301-0449
Electronic ISSN: 1432-1998
DOI: https://doi.org/10.1007/s00247-011-2167-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions

Abstract

Background

Purpose

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2011

Pediatric Radiology Continuing Medical Education Activity

Hermes

Renal safety in pediatric imaging: randomized, double-blind phase IV clinical trial of iobitridol 300 versus iodixanol 270 in multidetector CT

Caliceal diverticulum in pediatric patients: the spectrum of imaging findings

ELECTRICA: ELEctronic knowledge base for Clinical care, Teaching and Research In Child Abuse

Common and uncommon vascular rings and slings: a multi-modality review